Vascular Biogenics Ltd. (VBLT) Trading Down 4%
Vascular Biogenics Ltd. (NASDAQ:VBLT)’s share price dropped 4% on Friday . The stock traded as low as $4.04 and last traded at $4.07, with a volume of 107,716 shares changing hands. The stock had previously closed at $4.24.
VBLT has been the subject of several research reports. Roth Capital restated a “buy” rating and set a $22.00 price objective on shares of Vascular Biogenics in a research report on Thursday, June 9th. Chardan Capital restated a “buy” rating on shares of Vascular Biogenics in a research report on Tuesday, June 7th. Piper Jaffray Cos. restated a “buy” rating and set a $14.00 price objective on shares of Vascular Biogenics in a research report on Tuesday, June 7th. HC Wainwright initiated coverage on shares of Vascular Biogenics in a research report on Tuesday, June 28th. They set a “buy” rating and a $11.00 price objective for the company. Finally, Zacks Investment Research upgraded shares of Vascular Biogenics from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Thursday, August 18th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $13.67.
The stock’s market capitalization is $96.06 million. The company’s 50 day moving average price is $4.09 and its 200-day moving average price is $3.74.
Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.09. On average, equities research analysts predict that Vascular Biogenics Ltd. will post ($0.64) EPS for the current fiscal year.
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.